~~<i id='22022558F8'><strike id='22022558F8'><tt id='22022558F8'><pre id='22022558F8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：fashion 2025-09-27 10:05:28 - browse：55947

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Precocious puberty in girls comes with mental health risks

hotspot

focus

Wikipedia

hotspot

explore

AmandaAndrade-Rhoades/APU.S.regulatorsapprovedalabelexpansionforNovoNordisk’sobesitydrugWegovytotout

WSS

Female surgeons have lower rates of long

The Readout: Amylyx, Alumis, and Lundbeck drug updates

European regulators recommend Amylyx's ALS drug be rejected

What the Wegovy shortage looks like for doctors — and for patients

Precocious puberty in girls comes with mental health risks

Former medical device CEO who sold dummy, plastic parts convicted of fraud

hotspot

Wikipedia

hotspot

Drug repurposing or repositioning? The language matters

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Trump demands the U.S. pay no more for drugs than other countries … again

How to bring more disabled researchers into academia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The problem with charging patients to message their doctors

Affirmative action in medical school literally saved lives

Wellcome Trust names Røttingen as its new CEO

The cancer drug shortage isn’t new — and neither are the solutions

Humana CEO Bruce Broussard to step down in 2024

focus

Air quality improving but still lags in Black, Hispanic communities

Medicare to cover more brain scans related to Alzheimer’s drugs

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

What it’s like to watch children die of measles

How doctors and nurses shape Google's AI

Humana CEO Bruce Broussard to step down in 2024

Wikipedia

hotspot

hotspot

explore